[1]宋香妮,曹 娟△.恩替卡韦联合前列地尔治疗乙肝肝硬化合并肝源性糖尿病临床效果分析[J].陕西医学杂志,2020,49(9):1145-1148.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.023]
　SONG Xiangni,CAO Juan..Clinical effect of entecavir combined with alprostadil in the treatment of hepatitis B cirrhosis complicated with hepatogenous diabetes[J].,2020,49(9):1145-1148.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.023]
点击复制

恩替卡韦联合前列地尔治疗乙肝肝硬化合并肝源性糖尿病临床效果分析
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年9期
页码:
1145-1148
栏目:
药物与临床
出版日期:
2020-09-01

文章信息/Info

Title:
Clinical effect of entecavir combined with alprostadil in the treatment of hepatitis B cirrhosis complicated with hepatogenous diabetes
作者:
宋香妮; 曹 娟△
陕西省铜川市人民医院消化内科(铜川 727000)
Author(s):
SONG Xiangni; CAO Juan.
Department of Gastroenterology,Tongchuan People's Hospital,Shaanxi Province(Tongchuan 727000)
关键词:
乙肝肝硬化;  肝源性糖尿病;  恩替卡韦;  肝硬化;  乙肝;  预后
Keywords:
Hepatitis B cirrhosis;  Hepatogenic diabetes;  Entecavir;  Cirrhosis;  Hepatitis B;  Prognosis
分类号:
R575.2
DOI:
DOI:10.3969/j.issn.1000-7377.2020.09.023
文献标志码:
A
摘要:
目的:探讨恩替卡韦联合前列地尔治疗乙肝肝硬化合并肝源性糖尿病的临床效果。方法:选取75例乙肝肝硬化合并肝源性糖尿病患者,分为对照组(37例)和观察组(38例)。对照组在内科常规治疗的基础上给予恩替卡韦,观察组在对照组的基础上给予前列地尔,治疗12周。观察两组患者治疗前后的肝功能、肝纤维化及血糖水平等指标的变化。结果:两组谷丙转氨酶(GPT)、谷草转氨酶(GOT)均低于治疗前水平,白蛋白(ALB)均高于治疗前水平; Ⅲ型前胶原(PCⅢ)、透明质酸(HA)、层粘连蛋白(LN)水平均低于治疗前; 空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)水平均低于治疗前。同时,观察组上述指标水平均低于对照组,除FPG水平无统计学差异外,其他指标均有统计学差异(均P<0.05)。结论:恩替卡韦联合前列地尔治疗乙肝肝硬化合并肝源性糖尿病临床效果较好,可明显改善患者肝功能、肝纤维化及糖代谢。
Abstract:
Objective:To investigate the clinical effect of entecavir combined with alprostadil in the treatment of hepatitis B cirrhosis with hepatogenous diabetes.Methods:75 cases of hepatitis B cirrhosis patients complicated with hepatogenous diabetes were divided into control group(37 cases)and observation group(38 cases).The control group was given entecavir on the basis of conventional medical treatment,and the observation group was given alprostadil on the basis of the control group for 12 weeks.The changes of liver function index,liver fibrosis index and blood glucose level before and after treatment were observed.Results:The levels of alanine aminotransferase(ALT)and aspartate aminotransferase(AST)were lower than the pre-treatment levels,and albumin(ALB)was higher than the pre-treatment level.The levels of type Ⅲ procollagen(PCⅢ),hyaluronic acid(HA),laminin(LN)were lower than those before treatment.The levels of fasting blood glucose(FPG),2-hour postprandial glucose(2hPG)and glycosylated hemoglobin A1c(HbA1c)were lower than those before treatment.At the same time,the levels of the above mentioned indicators in the observation group were lower than those in the control group,with statistical difference(all P<0.05)except FDP.Conclusion:Entecavir combined with alprostadil has a good clinical effect in the treatment of hepatitis B cirrhosis complicated with hepatogenous diabetes,which can significantly improve liver function,liver fibrosis and glucose metabolism.

参考文献/References:

[1] Hickman IJ,Macdonald GA.Impact of diabetes on the severity of liver disease[J].Am J Med,2007,120(10):829-834.
[2] 范 丽,张 婷.拉米夫定、阿德福韦酯、恩替卡韦治疗失代偿期乙型肝炎肝硬化临床研究[J].陕西医学杂志,2019,48(7):939-941.
[3] 闫 宏,宁福军.恩替卡韦治疗乙肝肝硬化合并肝源性糖尿病的临床效果分析[J].中国当代医药,2016,23(12):107-109.
[4] 卓光伟.恩替卡韦对乙肝后肝硬化合并肝源性糖尿病患者肝功能和血糖水平的影响[J].河南医学研究,2019,28(2):300-302.
[5] 陈英刚,吕春苗,陈海君,等.恩替卡韦对乙型肝炎肝硬化伴肝源性糖尿病患者疗效及生化指标的影响[J].中华全科医学,2017,15(2):237-239.
[6] 韩少伟.恩替卡韦联合前列地尔治疗乙肝肝硬化腹水43例对血清炎症因子水平的影响[J].首都食品与医药,2019,26(16):82.
[7] 王富珍,郑 徽,孙校金,等.中国控制乙型病毒性肝炎的成就与展望[J].中国疫苗和免疫,2019,25(5):487-492.
[8] Gerich J.Postprandial hyperglycemia and cardiovasular disease[J].Endocr Pract,2006,12(1):47-51.
[9] 恩替卡韦临床应用专家委员会.恩替卡韦临床应用专家共识:2015年更新[J].临床肝胆病杂志,2016,32(1):32-39.
[10] 张国民,缪 宁,郑 徽,等.中国2005-2016年乙型病毒性肝炎报告发病的年龄和地区特征[J].中国疫苗和免疫,2018,24(2):121-126.
[11] 博?格丽,郝 云.共情护理及对症干预对病毒性肝硬化患者生活质量及自我认知的影响[J].当代护士,2020,27(3):101-103.
[12] Nishida T,Tsuji S,Tsujii M,et al.Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis[J].Am J Gastroenterol,2006,101(1):70-75.
[13] Wu Y,Liu J,Feng Y,et al.Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy:systematic review and network meta-analysis[J].Hepatol Int,2020,14(2):180-189.
[14] Huang SS,Xie DM,Cai YJ,et al.C-reactive protein-to-albumin ratio is a predictor of hepatitis B virus related decompensated cirrhosis:time-dependent receiver operating characteristics and decision curve analysis[J].Eur J Gastroenterol Hepatol,2017,29(4):472-480.
[15] Wachter DL,Kristiansen G,Soll C,et al.Insulin-like growth factor Ⅱ mRNA-binding protein 3(IMP3)expression in hepatocellular carcinoma.A clinicopathological analysis with emphasis on diagnostic value[J].Histopathology,2012,60(2):278-286.
[16] Roden M.Mechanisms of disease:hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance[J].Nat Clin Pract Endocrinol Metab,2006,2(6):335-348.
[17] 段成颖,赵文霞,杨明博.益气活血方联合恩替卡韦分散片治疗气虚血瘀证慢性乙型肝炎35例[J].中医研究,2018,31(9):21-23.
[18] 王国义.乙肝七因散联合拉米夫定治疗慢性乙型肝炎46例[J].陕西中医,2011,32(9):1111-1112.
[19] Jin SQ,Cao HL,Wang KB,et al.Preventative effects of prostaglandin E1 in combination with iodized olive oil on liver fibrosis aftertranscatheter arterial chemoembolization in a rabbit model of CCl4-induced liver fibrosis[J].Can J Physiol Pharmacol,2015,93(6):451-457.
[20] 陈 逊,刘海滨.前列地尔联合替比夫定对乙肝肝硬化患者疗效和血清炎性因子的影响[J].河北医学,2017,23(12):1963-1966.

相似文献/References:

[1]郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析*[J].陕西医学杂志,2019,(7):850.

更新日期/Last Update: 2020-09-02